Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that...
Pharmacyclics, Inc. (Nasdaq: PCYC) announced data from three Chronic Lymphocytic Leukemia (CLL) presentations at the American Society of Hematology (ASH) Annual Meeting describing the Btk-selective inhibitor PCI-32765. Two presentations report preclinical data, and one presentation reports...
Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the...
Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics introduced software and accessory items to enable the direct co-registration of images from multiple preclinical imaging modalities. This...
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of...
VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201...
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological activity of its HDAC, EGFR and HER2 inhibitor, CUDC-101, was published online in...
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus (HCV) protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique...
Regulus Therapeutics Inc. announced that new pre-clinical data from multiple therapeutic programs were presented at the "RNA Silencing: Mechanism, Biology and Application" Keystone Symposium held January 14 - 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing...
Regulus Therapeutics Inc. announced that new pre-clinical data from multiple therapeutic programs were presented at the "RNA Silencing: Mechanism, Biology and Application" Keystone Symposium held January 14 - 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing...
Regulus Therapeutics Inc. announced that new pre-clinical data from multiple therapeutic programs were presented at the "RNA Silencing: Mechanism, Biology and Application" Keystone Symposium held January 14 - 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing...